

version of the amended claims is attached as **Attachment A**:

A²

-- 4. (Amended) DNA-binding molecule according to claim 2 wherein said heterocyclic residue is chosen from pyrrole, imidazole, triazole, pyrazole, furan, thiazole, thiophene, oxazole, pyridine, or derivatives of any of these compounds wherein one or more of the heteroatoms are substituted by a substituent which is DNA-binding or non-DNA-binding.--

A³

-- 51. (Amended) Process for binding double-stranded DNA in a sequence-specific manner, comprising contacting a DNA-target sequence within said DNA with a DNA-binding molecule according to claim 1, in conditions allowing said binding to occur.--

A⁴

-- 69. (Amended) Process for modulating chromosome function in a eukaryotic cell, comprising the step of contacting a genomic DNA element, comprising a binding site mediating chromosome function, with a molecule according to claim 1 and having the capacity to bind in a sequence-specific manner to said element, said step of contacting being carried out in conditions permitting binding of said compound to said element, wherein the binding modulates chromosome function.--

--70. (Amended) Process for modulating the function of a DNA element in a eukaryotic cell, comprising the step of contacting a genomic DNA element, so-called "chromatin responsive element" (CRE), with a molecule according to claim 1 and having the capacity to bind in a sequence-specific manner to said CRE, said step of contacting being carried out in conditions